Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexavar in advanced anaplastic thyroid cancer
NCT00126568Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Sep 2011
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in anaplastic thyroid cancer (ATC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started Jun 2005; status: terminated.
02
Drugs
sorafenib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT00126568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126568.